Matches in Wikidata for { <http://www.wikidata.org/entity/Q59329010> ?p ?o ?g. }
- Q59329010 description "im Januar 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q59329010 description "scholarly article by Marco Matucci-Cerinic et al published 2018 in RMD open" @default.
- Q59329010 description "wetenschappelijk artikel" @default.
- Q59329010 description "наукова стаття, опублікована у 2018" @default.
- Q59329010 name "Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA" @default.
- Q59329010 name "Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA" @default.
- Q59329010 type Item @default.
- Q59329010 label "Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA" @default.
- Q59329010 label "Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA" @default.
- Q59329010 prefLabel "Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA" @default.
- Q59329010 prefLabel "Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA" @default.
- Q59329010 P1433 Q59329010-DB58BAC0-24FB-4847-BC7B-4A492EF3C371 @default.
- Q59329010 P1476 Q59329010-68263112-9E78-4345-91F6-8A29104937D6 @default.
- Q59329010 P2093 Q59329010-1A56D409-9CEF-4567-9F57-7E196B699E39 @default.
- Q59329010 P2093 Q59329010-212F84B5-B04B-452D-8FEB-1F285C040610 @default.
- Q59329010 P2093 Q59329010-6092689E-9A1A-4C93-9D19-1445E8C76866 @default.
- Q59329010 P2093 Q59329010-78932519-C69C-4F4D-B81D-1F3957B25F29 @default.
- Q59329010 P2093 Q59329010-7A4124B5-D71E-4D31-9F8D-00F9E0719D95 @default.
- Q59329010 P2093 Q59329010-93145C65-ACD1-475E-A894-95E2E6537F31 @default.
- Q59329010 P2093 Q59329010-B8DC29A5-E287-445A-8F25-D44114D9350E @default.
- Q59329010 P2093 Q59329010-EBD19183-E748-43C7-96ED-AC2A13A52D2E @default.
- Q59329010 P2860 Q59329010-040A922D-7F23-4947-9D31-C18584D60227 @default.
- Q59329010 P2860 Q59329010-0990623A-E711-4FBB-AB57-74C87E3DF287 @default.
- Q59329010 P2860 Q59329010-0B3282E3-A078-4C40-9EEA-980F0A9C01A8 @default.
- Q59329010 P2860 Q59329010-0C359781-03E6-40BD-B412-E04F814ED520 @default.
- Q59329010 P2860 Q59329010-246F3D73-13C5-4FDC-B519-5F02506EB9EF @default.
- Q59329010 P2860 Q59329010-3114BC44-B107-4C20-9AF8-BE5A8B1441F8 @default.
- Q59329010 P2860 Q59329010-337BF8BC-1E6C-4800-8F18-B6FB629491E0 @default.
- Q59329010 P2860 Q59329010-34397A91-BC6E-499E-A43B-BA737B94C955 @default.
- Q59329010 P2860 Q59329010-3F5A55D6-5A60-4989-BB2A-38A3D37325F0 @default.
- Q59329010 P2860 Q59329010-4FB83BFC-E524-4C37-82BB-27477EB5A7DA @default.
- Q59329010 P2860 Q59329010-50081411-35BC-491C-A1FE-BB83454AEC64 @default.
- Q59329010 P2860 Q59329010-6485EBA5-D706-4F3A-8365-510BE28402EB @default.
- Q59329010 P2860 Q59329010-67D94841-060F-4316-88B8-5BA3925C4D43 @default.
- Q59329010 P2860 Q59329010-767BD310-6DC1-4F65-BDAF-26370342BCCA @default.
- Q59329010 P2860 Q59329010-7A317A47-258D-422E-AC50-D4EBEE37261F @default.
- Q59329010 P2860 Q59329010-878EBECF-7DE9-4EC9-AAF7-22AA68461912 @default.
- Q59329010 P2860 Q59329010-8F272244-A102-4104-BB2A-974B8DA24FC8 @default.
- Q59329010 P2860 Q59329010-972C2C51-22F4-4F7A-956C-6632F70C15C6 @default.
- Q59329010 P2860 Q59329010-A74F7E82-786D-4D9F-A65E-6FF546DDD1FD @default.
- Q59329010 P2860 Q59329010-B3904451-85A4-47D3-A4DF-33C85DB29169 @default.
- Q59329010 P2860 Q59329010-BD523120-830F-4391-81A2-11E8AA453004 @default.
- Q59329010 P2860 Q59329010-BE0CE489-42F7-43AF-99FE-8D9B612093A1 @default.
- Q59329010 P2860 Q59329010-CB4E58BC-6C50-4FF4-905C-BC4B2572F6AE @default.
- Q59329010 P2860 Q59329010-DA185B57-45E5-4F43-9B1D-724A96740243 @default.
- Q59329010 P2860 Q59329010-E10DD804-1515-4CBB-B419-BD0261C64C42 @default.
- Q59329010 P304 Q59329010-328947BE-2314-43F0-BFA5-25CF6DBF37FE @default.
- Q59329010 P31 Q59329010-1BD4CC05-D678-47CF-A132-BE34DDB95321 @default.
- Q59329010 P356 Q59329010-85BE55CB-3130-496E-A7F8-86B37EF8435D @default.
- Q59329010 P407 Q59329010-9325EF0E-D308-4891-9B66-AC917ACFDDE7 @default.
- Q59329010 P433 Q59329010-A5D27420-FF97-4AFA-B9EA-C83A6633500D @default.
- Q59329010 P478 Q59329010-F90C2578-58BB-4E25-A79B-615548E15180 @default.
- Q59329010 P50 Q59329010-6D29CAA9-01D8-4976-9C16-F8747257C03B @default.
- Q59329010 P50 Q59329010-970AA79E-F744-43A9-8096-653AA5ECAA84 @default.
- Q59329010 P50 Q59329010-A87615F2-C128-491D-982C-AC4D4461F35F @default.
- Q59329010 P577 Q59329010-C0F1403F-F884-421B-8255-83869806CEA7 @default.
- Q59329010 P698 Q59329010-B2D0B01B-E2DE-4D25-BF56-52683A838BED @default.
- Q59329010 P921 Q59329010-2EE2A688-8D26-4DC3-8A53-7E1C8E11D359 @default.
- Q59329010 P932 Q59329010-7AC16BF5-C73E-4E0D-BC02-FF3D9559383F @default.
- Q59329010 P356 RMDOPEN-2018-000757 @default.
- Q59329010 P698 30487998 @default.
- Q59329010 P1433 Q27726913 @default.
- Q59329010 P1476 "Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA" @default.
- Q59329010 P2093 "Adanna Davis" @default.
- Q59329010 P2093 "Arnd Schwebig" @default.
- Q59329010 P2093 "Arthur Kavanaugh" @default.
- Q59329010 P2093 "Goran Babic" @default.
- Q59329010 P2093 "Heike Woehling" @default.
- Q59329010 P2093 "Hendrik Schulze-Koops" @default.
- Q59329010 P2093 "Johann Poetzl" @default.
- Q59329010 P2093 "Yannick Allanore" @default.
- Q59329010 P2860 Q26864171 @default.
- Q59329010 P2860 Q28295474 @default.
- Q59329010 P2860 Q34315745 @default.
- Q59329010 P2860 Q34361336 @default.
- Q59329010 P2860 Q34662758 @default.
- Q59329010 P2860 Q35190102 @default.
- Q59329010 P2860 Q35637985 @default.
- Q59329010 P2860 Q37206622 @default.
- Q59329010 P2860 Q37321197 @default.
- Q59329010 P2860 Q37604518 @default.
- Q59329010 P2860 Q37695053 @default.
- Q59329010 P2860 Q44003346 @default.
- Q59329010 P2860 Q46944131 @default.
- Q59329010 P2860 Q50098933 @default.
- Q59329010 P2860 Q51051064 @default.
- Q59329010 P2860 Q51359715 @default.
- Q59329010 P2860 Q53170870 @default.
- Q59329010 P2860 Q54967818 @default.
- Q59329010 P2860 Q56879288 @default.
- Q59329010 P2860 Q63101754 @default.
- Q59329010 P2860 Q68109843 @default.
- Q59329010 P2860 Q73206828 @default.
- Q59329010 P2860 Q73235899 @default.
- Q59329010 P2860 Q74455180 @default.
- Q59329010 P2860 Q84709013 @default.
- Q59329010 P304 "e000757" @default.
- Q59329010 P31 Q13442814 @default.
- Q59329010 P356 "10.1136/RMDOPEN-2018-000757" @default.
- Q59329010 P407 Q1860 @default.